Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A phase 2 trial of Orca-T in myelodysplastic syndromes / neoplasms, run by Orca Biosystems, Inc., now recruiting.
Overview
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 2 interventional study registered as NCT07216443 by Orca Biosystems, Inc., with 80 participants planned, started 2025-12-09 and due to reach its primary completion in 2027-11. Interventions recorded: Orca-T.
Similar pages
not linked directly; found by shared links- TrialPrecision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Shares Orca Biosystems, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialPBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialRVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialStudy of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.